Autolus Therapeutics has found a deep-pocketed supporter of its CD19 CAR-T therapy. Having seen Autolus’ stock halved over the past year, Blackstone Life Sciences has stepped in with a $250 million package to support the British biotech through to a pivotal readout and beyond. The deal covers obecabtagene autoleucel, a CD19 CAR-T therapy also known as obe-cel and AUTO1. Source: Fierce Biotech 8/11/2021